Alliancebernstein L.P. boosted its stake in XBiotech Inc. (NASDAQ:XBIT) by 130.1% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 42,800 shares of the biopharmaceutical company’s stock after buying an additional 24,200 shares during the quarter. Alliancebernstein L.P. owned approximately 0.12% of XBiotech worth $201,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently bought and sold shares of XBIT. LMR Partners LLP purchased a new stake in XBiotech in the 2nd quarter valued at approximately $123,000. American International Group Inc. lifted its stake in XBiotech by 7.1% in the 1st quarter. American International Group Inc. now owns 10,764 shares of the biopharmaceutical company’s stock valued at $177,000 after buying an additional 709 shares in the last quarter. KCG Holdings Inc. purchased a new stake in XBiotech in the 1st quarter valued at approximately $186,000. Bank of New York Mellon Corp lifted its stake in XBiotech by 2.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 73,451 shares of the biopharmaceutical company’s stock valued at $345,000 after buying an additional 1,883 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in XBiotech by 670.5% in the 1st quarter. JPMorgan Chase & Co. now owns 24,840 shares of the biopharmaceutical company’s stock valued at $410,000 after buying an additional 21,616 shares in the last quarter. 10.68% of the stock is currently owned by hedge funds and other institutional investors.

Shares of XBiotech Inc. (NASDAQ:XBIT) opened at $3.97 on Tuesday. XBiotech Inc. has a 52 week low of $2.77 and a 52 week high of $20.18.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/11/14/alliancebernstein-l-p-buys-24200-shares-of-xbiotech-inc-xbit.html.

About XBiotech

XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response.

Institutional Ownership by Quarter for XBiotech (NASDAQ:XBIT)

Receive News & Ratings for XBiotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.